Johnson & Johnson (NYSE:JNJ), $JNJ, is growing according to the latest weekly edition by EuroBiotech. Even with its already burgeoning network there seems to be much more behind the scenes. Its latest shop set up at Karolinska Institutet in Stockholm has come as a surprise to many. Its aim is to establish a group that will help bring the shepherd academic innovations into commercial development.
Various activities related to the J&J-Karolinska Institutet alliance took place within the Nordic region as you shall see below: –
- Setting up of innovation hub at Karolinska Institutet.
The hub is within the Swedish medical university as an outpost. From here, J&J will be able to make a follow up on the academic research breakthroughs and probably drive in any support that may be required for the advancement of ideas.
- Diabetes and Obesity R & D collaboration have been scrapped off by Lilly and Zealand
Eli Lilly and Zealand Pharma will no longer have diabetes and obesity-focused collaboration. Since 2013, the two Companies have been on a mission to explore how to treat Type 2 diabetes and obesity. However, they have both agreed and concluded that they will not pursue the program anymore.
- Mapi Pharma is closed on a $10M Series A round.
This was to finance mid-phase trials. The trials usually took place once in a month and on a Teva’s blockbuster multiple sclerosis drugs, Copaxone version. This resulted from two abandoned endeavors to increase cash in a Nasdaq IPO.
- Talk about interest in a Big Pharma buyout by Bavarian Nordic is quashed.
Bavarian Nordic is a vaccine player that has been eyeing to become a European biotech that would be taken by a well financially loaded suitor. For the last few years, Bavarian Nordic has had deals with Bristol-Myers Squibb and Johnson & Johnson.
- German takes the lead in having the most influential Pharma Research Institutions.
German institutions are on the lead in Thomson Reuters’ list being the most prominent pharma research centers. They garnered the top 4 positions.